

05 June 2026

To  
BSE Limited,  
Compliance Department,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400001  
Scrip Code No – 509486

**Dear Sir/Madam,**

**Sub: Intimation of lapse & forfeiture of 3,15,000 Warrants**

**Re: Disclosure under Regulation 30 read with Schedule III to the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in continuation of the Company's earlier intimation dated 03 December 2024 and 05 December 2024, wherein the Company had informed the Stock Exchanges regarding the allotment of 48,00,000 (Forty-Eight Lakhs) Warrants to Bilcare Limited (Promoter) at an issue price of ₹200/- per warrant, aggregating to ₹96,00,00,000/- (Rupees Ninety-Six Crores only).

In accordance with the terms of issue and Regulation 169(2) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations"), 25% of the issue price was received upfront as the initial subscription amount at the time of allotment of warrants and the balance 75% was payable upon exercise of options against the warrants to subscribe to equity shares, within a period of 18 months from the date of allotment of warrants, i.e., on or before 04 June 2026.

As the Company has not received the balance 75% of the consideration from Bilcare Limited within the stipulated timeline, the balance 3,15,000 warrants remaining outstanding have lapsed on expiry of the exercise period on 04 June 2026. Consequently, the upfront subscription amount paid in respect of such warrants, aggregating to ₹1,57,50,000, stands forfeited and shall be retained by the Company in accordance with the terms of issue and the applicable provisions of the SEBI ICDR Regulations. The Board of Directors of the Company through Resolution by Circulation passed on 05 June 2026 approved the forfeiture of 3,15,000 warrants which remained outstanding and have lapsed on expiry of the exercise period on 04 June 2026.

Further, consequent to the lapse of the aforesaid warrants, the warrant holder(s) shall cease to have any right or entitlement to seek conversion of the warrants into equity shares of the Company. There shall be no change in the paid-up equity share capital of the Company pursuant to the lapse of the warrants. The forfeited amount shall continue to be retained by the Company and accounted for in accordance with the applicable accounting standards and regulatory requirements.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed as Annexure A.

You are requested to take the above information on record.

Thanking you,

Yours faithfully,

**For Caprihans India Limited,**

Rajesh P. Likhite  
Company Secretary & Compliance Officer

Encl: as above

**Annexure-A**

<b>S. No.</b>	<b>Particulars</b>	<b>Disclosures</b>
1.	Type of securities	Convertible Warrants
2.	Type of issuance	Preferential allotment
3.	Total number of warrants originally allotted	48,00,000
4.	Issue price per warrant	₹200/- per warrant
5.	Date of allotment	03 December 2024 and 05 December 2024
6.	Tenure	18 Months (Eighteen Months)
7.	Number of warrants exercised	44,85,000
8.	Number of warrants lapsed	3,15,000
9.	Name of warrant holder whose warrants have lapsed	Bilcare Limited
10.	Amount forfeited	₹1,57,50,000/-
11.	Any change in capital structure	There is no change in the paid-up equity share capital of the Company pursuant to the above lapse of warrants.

**For Caprihans India Limited**

Rajesh P. Likhite  
Company Secretary & Compliance Officer